Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 113

Similar articles for PubMed (Select 12585949)

1.

Effects of initiating carvedilol in patients with severe chronic heart failure: results from the COPERNICUS Study.

Krum H, Roecker EB, Mohacsi P, Rouleau JL, Tendera M, Coats AJ, Katus HA, Fowler MB, Packer M; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group.

JAMA. 2003 Feb 12;289(6):712-8.

PMID:
12585949
2.

Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.

Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group.

Circulation. 2002 Oct 22;106(17):2194-9.

3.

Effect of carvedilol on survival in severe chronic heart failure.

Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL; Carvedilol Prospective Randomized Cumulative Survival Study Group.

N Engl J Med. 2001 May 31;344(22):1651-8.

5.

The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group.

Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH.

N Engl J Med. 1996 May 23;334(21):1349-55.

6.

Double-blind, placebo-controlled study of the long-term efficacy of carvedilol in patients with severe chronic heart failure.

Krum H, Sackner-Bernstein JD, Goldsmith RL, Kukin ML, Schwartz B, Penn J, Medina N, Yushak M, Horn E, Katz SD, et al.

Circulation. 1995 Sep 15;92(6):1499-506.

7.

Pre-discharge initiation of beta-blocker therapy in elderly patients hospitalized for acute decompensation of chronic heart failure: an effective strategy for the implementation of beta-blockade in heart failure.

Tarantini L, Cioffi G, Opasich C, Di Lenarda A, Pulignano G, Del Sindaco D, De Feo S, Stefenelli C, Russo P, Catania G.

Ital Heart J. 2004 Jun;5(6):441-9.

PMID:
15320569
8.

Efficacy and safety of carvedilol in treatment of heart failure with chronic kidney disease: a meta-analysis of randomized trials.

Wali RK, Iyengar M, Beck GJ, Chartyan DM, Chonchol M, Lukas MA, Cooper C, Himmelfarb J, Weir MR, Berl T, Henrich WL, Cheung AK.

Circ Heart Fail. 2011 Jan;4(1):18-26. doi: 10.1161/CIRCHEARTFAILURE.109.932558. Epub 2010 Oct 29.

9.

Carvedilol: a review of its use in chronic heart failure.

Keating GM, Jarvis B.

Drugs. 2003;63(16):1697-741. Review.

PMID:
12904089
10.

Low-dose carvedilol improves left ventricular function and reduces cardiovascular hospitalization in Japanese patients with chronic heart failure: the Multicenter Carvedilol Heart Failure Dose Assessment (MUCHA) trial.

Hori M, Sasayama S, Kitabatake A, Toyo-oka T, Handa S, Yokoyama M, Matsuzaki M, Takeshita A, Origasa H, Matsui K, Hosoda S; MUCHA Investigators.

Am Heart J. 2004 Feb;147(2):324-30.

PMID:
14760332
11.
12.

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

Packer M, Colucci WS, Sackner-Bernstein JD, Liang CS, Goldscher DA, Freeman I, Kukin ML, Kinhal V, Udelson JE, Klapholz M, Gottlieb SS, Pearle D, Cody RJ, Gregory JJ, Kantrowitz NE, LeJemtel TH, Young ST, Lukas MA, Shusterman NH.

Circulation. 1996 Dec 1;94(11):2793-9.

13.

Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET.

Torp-Pedersen C, Poole-Wilson PA, Swedberg K, Cleland JG, Di Lenarda A, Hanrath P, Komajda M, Lutiger B, Metra M, Remme WJ, Scherhag A, Skene A; COMET Investigators.

Am Heart J. 2005 Feb;149(2):370-6.

PMID:
15846279
14.

Safety and efficacy of carvedilol in severe heart failure. The U.S. Carvedilol Heart Failure Study Group.

Cohn JN, Fowler MB, Bristow MR, Colucci WS, Gilbert EM, Kinhal V, Krueger SK, Lejemtel T, Narahara KA, Packer M, Young ST, Holcslaw TL, Lukas MA.

J Card Fail. 1997 Sep;3(3):173-9.

PMID:
9330125
15.

Efficacy and safety of bisoprolol fumarate compared with carvedilol in Japanese patients with chronic heart failure: results of the randomized, controlled, double-blind, Multistep Administration of bisoprolol IN Chronic Heart Failure II (MAIN-CHF II) study.

Hori M, Nagai R, Izumi T, Matsuzaki M.

Heart Vessels. 2014 Mar;29(2):238-47. doi: 10.1007/s00380-013-0340-3. Epub 2013 Apr 5. Erratum in: Heart Vessels. 2014 Mar;29(2):248.

PMID:
23559359
16.

Carvedilol for children and adolescents with heart failure: a randomized controlled trial.

Shaddy RE, Boucek MM, Hsu DT, Boucek RJ, Canter CE, Mahony L, Ross RD, Pahl E, Blume ED, Dodd DA, Rosenthal DN, Burr J, LaSalle B, Holubkov R, Lukas MA, Tani LY; Pediatric Carvedilol Study Group.

JAMA. 2007 Sep 12;298(10):1171-9.

PMID:
17848651
17.

Influence of pretreatment systolic blood pressure on the effect of carvedilol in patients with severe chronic heart failure: the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study.

Rouleau JL, Roecker EB, Tendera M, Mohacsi P, Krum H, Katus HA, Fowler MB, Coats AJ, Castaigne A, Scherhag A, Holcslaw TL, Packer M; Carvedilol Prospective Randomized Cumulative Survival Study Group.

J Am Coll Cardiol. 2004 Apr 21;43(8):1423-9.

PMID:
15093878
18.

Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure.

Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow MR, Cohn JN, Lukas MA, Young ST, Packer M; U.S. Carvedilol Heart Failure Study Group.

N Engl J Med. 2001 May 3;344(18):1358-65.

19.

Tolerability of carvedilol and ACE-Inhibition in mild heart failure. Results of CARMEN (Carvedilol ACE-Inhibitor Remodelling Mild CHF EvaluatioN).

Komajda M, Lutiger B, Madeira H, Thygesen K, Bobbio M, Hildebrandt P, Jaarsma W, Riegger G, Rydén L, Scherhag A, Soler-Soler J, Remme WJ; CARMEN investigators and co-ordinators.

Eur J Heart Fail. 2004 Jun;6(4):467-75.

PMID:
15182773
20.

[The effects of mid- and long-term administration (3-4 years) of carvedilol in patients with idiopathic dilated cardiomyopathy].

Metra M, Nodari S, Garbellini M, Boldi E, Rosselli F, Milan E, Giubbini R, Dei Cas L.

Cardiologia. 1997 May;42(5):503-12. Italian.

PMID:
9289367
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk